Emerging Markets Help Fresenius Kabi Offset US Pressures
As Firm Pushes Back Expectations For Biosimilars By A Year
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
